• Viatris recently showcased six presentations at the 2026 ACOG Annual Clinical & Scientific Meeting in Washington, highlighting positive Phase 3 efficacy, safety, adhesion, pharmacokinetic and cycle control data for its investigational low-dose estrogen weekly contraceptive patch.
• The company also secured FDA acceptance of its New Drug Application for the patch with a July 30, 2026 target action date, underscoring how women’s health innovation is becoming a more visible part of Viatris’ pipeline story.
• We’ll now examine how this late-stage contraceptive patch progress, including the FDA’s accepted review, may influence Viatris’ broader investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Viatris Investment Narrative Recap

To own Viatris, you need to believe that a largely mature generics business can steadily fund and absorb a shift toward higher value products while managing pricing and regulatory pressure. In the near term, the FDA decision on the low dose contraceptive patch looks like a key catalyst, while ongoing margin pressure and operational issues remain the biggest risks. The latest contraceptive data and FDA review acceptance appear supportive, but do not remove those broader pressures.

Among recent developments, the FDA’s acceptance of Viatris’ New Drug Application for the weekly contraceptive patch, with a July 30, 2026 action date, stands out. It ties directly into the women’s health data presented at ACOG and gives investors a clear timeline for a potential branded product decision that could modestly counterbalance reliance on older, off patent drugs if it progresses as planned.

Yet in contrast to the promise of new products, investors should also be aware that...

Viatris' narrative projects $15.3 billion revenue and $1.2 billion earnings by 2029.

Uncover how Viatris' forecasts yield a $15.72 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most cautious analysts were assuming roughly flat revenues near US$14.3 billion and only US$94.2 million in earnings by 2028, so this women’s health news could eventually challenge their more pessimistic view that Viatris remains heavily tied to low growth, mature products.

Explore 7 other fair value estimates on Viatris - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.